Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Jun;22(6):e25297.
doi: 10.1002/jia2.25297.

Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study

Jose R Castillo-Mancilla  1 , Andrew N Phillips  2 , James D Neaton  3 , Jacqueline Neuhaus  3 , Shweta Sharma  3 , Jason V Baker  4   5 , Simon Collins  6 , Sharon Mannheimer  7 , Sarah Pett  2   8   9 , Veronique Touzeau-Römer  10 , Mark N Polizzotto  9 , Jens D Lundgren  11 , Edward M Gardner  12 ; INSIGHT START Study Group
Affiliations
Randomized Controlled Trial

Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study

Jose R Castillo-Mancilla et al. J Int AIDS Soc. 2019 Jun.

Abstract

Introduction: Suboptimal ART adherence, despite HIV viral suppression, has been associated with chronic residual inflammation. Whether this association extends to individuals who initiate ART during early HIV infection remains unknown, which was the objective of this study.

Methods: Plasma levels of interleukin-6 (IL-6), high-sensitivity C-reactive protein, serum amyloid A protein (SAA), IL-27, soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, D-dimer and the CD4+/CD8+ T-cell ratio, were analysed at baseline and eight months after ART initiation in treatment-naïve participants with HIV and CD4+ T-cells >500 cells/mm3 enrolled in the immediate arm of START. Adherence was assessed by seven-day self-report. Multivariable linear regression was utilized to analyse the association between ART adherence and each biomarker at the eight-month visit in participants who achieved virologic suppression (<50 copies/mL).

Results: We evaluated 1627 participants (422 female) who achieved virologic suppression at the eight-month visit in the period between 2009 and 2013. Median (IQR) CD4+ T-cell count before ART was 651 (585, 769) cells/mm3 . Incomplete adherence was reported in 109 (7%) participants at the eight month visit. After adjusting for covariates, plasma IL-6 was 1.12 (95% CI, 1.00 to 1.26; p = 0.047) fold higher in participants reporting incomplete versus 100% adherence. A similar association for SAA was observed in an exploratory analysis (1.29 (95% CI 1.04 to 1.60); p = 0.02). No significant differences in other biomarkers were observed.

Conclusions: Incomplete ART adherence was associated with higher IL-6 levels in individuals who achieved virologic suppression early after ART initiation in START. A potential similar association for SAA requires confirmation. These findings suggest a role for identifying strategies to maximize ART adherence even during virologic suppression. ClinicalTrials.gov number: NCT00867048.

Keywords: START study; adherence; antiretroviral therapy; inflammation; inteleukin-6; serum amyloid A protein.

PubMed Disclaimer

References

    1. Wada N, Jacobson LP, Cohen M, French A, Phair J, Munoz A. Cause‐specific mortality among HIV‐infected individuals, by CD4(+) cell count at HAART initiation, compared with HIV‐uninfected individuals. AIDS. 2014;28(2):257–65. - PMC - PubMed
    1. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43(1):27–34. - PubMed
    1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Antiretroviral therapy for the prevention of HIV‐1 transmission. N Engl J Med. 2016;375(9):830–9. - PMC - PubMed
    1. Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201(12):1788–95. - PMC - PubMed
    1. Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, et al. Soluble markers of inflammation and coagulation but not T‐cell activation predict non‐AIDS‐defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014;210(8):1248–59. - PMC - PubMed

Publication types

Associated data